BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 23084816)

  • 1. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
    Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
    JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
    Bonello L; Laine M; Baumstarck K; Fernandez J; Maillard L; Peyrol M; Bessereau J; Aradi D; Camilleri E; Roubille F; Piot C; Paganelli F; Camoin-Jau L; Dignat-George F
    Int J Cardiol; 2013 Oct; 168(4):4244-8. PubMed ID: 23911273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
    Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
    Pankert M; Quilici J; Loundou AD; Verdier V; Lambert M; Deharo P; Bonnet G; Gaborit B; Morange PE; Valéro R; Dutour A; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2014 Jan; 113(1):54-9. PubMed ID: 24182762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.
    Diodati JG; Saucedo JF; French JK; Fung AY; Cardillo TE; Henneges C; Effron MB; Fisher HN; Angiolillo DJ
    Circ Cardiovasc Interv; 2013 Oct; 6(5):567-74. PubMed ID: 24065443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up.
    Koziński M; Obońska K; Stankowska K; Navarese EP; Fabiszak T; Stolarek W; Kasprzak M; Siller-Matula JM; Rość D; Kubica J; De Servi S
    Cardiol J; 2014; 21(5):547-56. PubMed ID: 24671900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
    Dridi NP; Johansson PI; Clemmensen P; Stissing T; Radu MD; Qayyum A; Pedersen F; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2014; 25(7):506-12. PubMed ID: 24245960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes.
    Cuisset T; Quilici J; Loosveld M; Gaborit B; Grosdidier C; Fourcade L; Gil JM; Moro PJ; Morange PE; Bonnet JL; Alessi MC
    Am Heart J; 2012 Sep; 164(3):327-33. PubMed ID: 22980298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
    Abtan J; Silvain J; Kerneis M; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Collet JP; Montalescot G
    Thromb Haemost; 2013 Nov; 110(5):1055-64. PubMed ID: 23925438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.